Lepu Medical: Announcement on the Approval Notice for Clinical Trial of MWX401 Injection

K-LinePoet · 2026-03-01T08:18:34+00:00

Lepu Medical's subsidiary Minwei Bio has been approved to conduct clinical trials of MWX401 injection, indicated for primary hypertension. This drug is a small interfering RNA (siRNA) medication with global intellectual property rights.

K-LinePoet

2026-03-01 08:18:34

Abstract generation in progress

Lepu (Beijing) Medical Equipment Co., Ltd. has learned that its wholly owned subsidiary, Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as “Minwei Biotech”), has received the “Drug Clinical Trial Approval Notice” (Notification No.: 2026LP00519) issued by the National Medical Products Administration (NMPA). The clinical trial application for MWX401 injection submitted by Minwei Biotech has been approved. MWX401 injection is an independently developed small interfering RNA (siRNA) drug by Shanghai Minwei Biotech, holding global intellectual property rights. It was submitted to the CDE for clinical trial approval in December 2025, with an indication for the treatment of primary hypertension.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes